The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable.
Where this comes from
- Record sourced from PubMed, PMID 34464211.
- Also identified by DOI 10.18553/jmcp.2021.27.9.1321 and PMC identifier 10391150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES</b>: No funding was provided for the writing of this commentary. In this commentary, the author refers to CivicaRx, for which Mayo Clinic is a founding member. As an employee of Mayo Clinic, the author does not have any direct financial relationship with or support from CivicaRx.
Medical subject headings
- Cost of Illness
- Drug Costs
- Multiple Myeloma